Artelo Biosciences announced that it has selected Worldwide Clinical Trials to support the Company’s planned Phase 1 trial with ART26.12, its Fatty Acid Binding Protein 5 inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARTL:
- Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
- Artelo Biosciences presents new preclinical data on ART12.11
- Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Artelo Biosciences reports Q3 EPS (83c), consensus (65c)
- Artelo Biosciences announces publication of peer-reviewed research on ART27.13
